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Health Status Disparities by Sex,
Race/Ethnicity, and Socioeconomic
Status in Outpatients With Heart Failure
Yevgeniy Khariton, MD,a Michael E. Nassif, MD,b Laine Thomas, PHD,c Gregg C. Fonarow, MD,d Xiaojuan Mi, PHD,c
Adam D. DeVore, MD, MHS,c,e Carol Duffy, DO,f Puza P. Sharma, MBBS, MPH, PHD,f Nancy M. Albert, PHD,g
J. Herbert Patterson, PHARMD,h Javed Butler, MD, MPH,i Adrian F. Hernandez, MD, MHS,c,e
Fredonia B. Williams, EDD,j Kevin McCague, MA,f John A. Spertus, MD, MPHa

ABSTRACT
OBJECTIVES This study sought to describe the health status of outpatients with heart failure and reduced ejection
fraction (HFrEF) by sex, race/ethnicity, and socioeconomic status (SES).
BACKGROUND Although a primary goal in treating patients with HFrEF is to optimize health status, whether disparities
by sex, race/ethnicity, and SES exist is unknown.
METHODS In the CHAMP-HF (Change the Management of Patients with Heart Failure) registry, the associations among
sex, race, and SES and health status, as measured by the Kansas City Cardiomyopathy Questionnaire-overall summary
(KCCQ-os) score (range 0 to 100; higher scores indicate better health status) was compared among 3,494 patients from
140 U.S. clinics. SES was categorized by total household income. Hierarchical multivariate linear regression estimated
differences in KCCQ-os score after adjusting for 31 patient characteristics and 10 medications.
RESULTS Overall mean KCCQ-os scores were 64.2  24.0 but lower for women (29% of sample; 60.3  24.0 vs. 65.9
 24.0, respectively; p < 0.001), for blacks (60.5  25.0 vs. 64.9  23.0, respectively; p < 0.001), for Hispanics (59.1 
21.0 vs. 64.9  23.0, respectively; p < 0.001), and for those with the lowest income (<$25,000; mean: 57.1 vs. 63.1 to
74.7 for other income categories; p < 0.001). Fully adjusted KCCQ-os scores were 2.2 points lower for women (95%
conﬁdence interval [CI]: 3.8 to 0.6; p ¼ 0.007), no different for blacks (p ¼ 0.74), 4.0 points lower for Hispanics
(95% CI: 6.6 to 1.3; p ¼ 0.003), and lowest in the poorest patients (4.7 points lower than those with the highest
income (95% CI: 0.1 to 9.2; p ¼ 0.045; p for trend ¼ 0.003).
CONCLUSIONS Among outpatients with HFrEF, women, blacks, Hispanics, and poorer patients had worse health
status, which remained signiﬁcant for women, Hispanics, and poorer patients in fully adjusted analyses. This suggests an
opportunity to further optimize treatment to reduce these observed disparities. (J Am Coll Cardiol HF 2018;6:465–73)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A

ABBREVIATIONS
AND ACRONYMS
CI = conﬁdence interval

primary goal of U.S. health care, as

performance

articulated by the Department of

health status disparities.

can

successfully

reduce

Health and Human Services’ Healthy

People 2020 initiative, is to eradicate dispar-

HFrEF = heart failure and

measures

METHODS

ities in health status by sex, race/ethnicity,

reduced ejection fraction

and socioeconomic status (SES) (1). Prior

STUDY DESIGN. CHAMP-HF, as previously described,

Cardiomyopathy

studies have demonstrated worse outcomes,

is a multicenter, observational registry developed

Questionnaire-overall

principally

hospitalization

with the primary objective of capturing the outcomes

summary score

rates, in women, blacks, Hispanics, and pa-

and real-world treatment patterns of patients with

LVEF = left ventricular ejection

tients with lower SES in the setting of heart

HFrEF in the United States (5). Brieﬂy, patients with

failure (2,3). However, a primary treatment

chronic HFrEF (left ventricular ejection fraction

goal in heart failure is to optimize patients’

[LVEF] #40%) being treated with at least 1 guideline-

health status, including their symptoms, function,

recommended pharmacotherapy were consecutively

and quality of life. To date, no studies have described

recruited from outpatient heart failure clinics. Sub-

the health status of patients with heart failure and

jects were excluded if they were enrolled in a hospice

reduced ejection fraction (HFrEF) in routine clinical

program or estimated to have a life expectancy of <1

care. Given the many potential interventions avail-

year or had a history of heart transplantation, left

able to improve the health status of patients with

ventricular assist device implantation, or end-stage

HFrEF, identifying differences by sex, race/ethnicity,

kidney disease requiring hemodialysis. Eligible sites

or SES can highlight new opportunities to further

were identiﬁed based upon the completion of a

reduce these disparities in care.

feasibility survey, which provided investigators with

KCCQ-os = Kansas City

fraction

SES = socioeconomic status

mortality

and

the opportunity to ensure broad geographic and

SEE PAGE 474

provider specialty representation. Study coordinators
To address this gap in knowledge, we compared

at each site were responsible for identiﬁcation and

the health status of patients with HFrEF by sex,

enrollment of subjects during the course of a sched-

race/ethnicity, and SES in the CHAMP-HF (Change

uled outpatient visit. CHAMP-HF was sponsored by

the Management of Patients with Heart Failure)

Novartis Pharmaceuticals Corp., and all participating

registry. CHAMP-HF is a large, prospective, multi-

sites obtained local or central institutional review

center, observational study of outpatients with

board approval before subject enrollment as well as

HFrEF that captured patients’ health status by

informed consent from each participant. This study

using the short form of the Kansas City Cardiomy-

leveraged baseline data from all patients enrolled

opathy Questionnaire-12 (KCCQ-12), a well-validated

before March 6, 2017.

measurement of patients’ symptoms, function, and

DATA COLLECTION. At the time of study subject

quality of life (4). Moreover, as payers increasingly

enrollment, site coordinators interviewed patients to

turn to patient-reported outcome measures, such

collect their self-identiﬁed race/ethnicity as well as

as the KCCQ-12 instrument, to quantify health care

household income and health status and abstracted

quality, identifying populations of patients with

their clinical history and medications. The primary

worse health status can form the foundation with

outcome for this analysis was disease-speciﬁc health

which

status, as assessed by the 12-item KCCQ-12. The

to

evaluate

whether

the

use

of

such
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T A B L E 1 Distribution of Patient Characteristics (N ¼ 3,494)

T A B L E 1 Continued

Age, yrs

Number of prior hospitalizations within 12 months of screening

<40

68.0 (59.0, 75.0)
111 (3.2)

0

2,173 (62.2)

40–64

1,307 (37.4)

1

886 (25.4)

65–80

1,638 (46.9)

$2

435 (12.4)

>80

438 (12.5)

Vital signs on enrollment

Male

2,473 (70.8)

Systolic pressure, mm Hg

120 (110, 131)

White

2,616 (74.9)

Diastolic pressure, mm Hg

72 (64, 80)

Black

572 (16.4)

Heart rate, beats/min

72 (66, 81)

Hispanic

589 (16.9)

BMI, kg/m2

29.2 (25.5, 33.8)

Clinical measurements and laboratory results
LVEF, %
NT-proBNP, pg/ml

Insurance status

30 (23, 35)
2,013 (794, 5,490)

Managed care

574 (16.4)

HbA1c, %

6.4 (5.8, 7.6)

Private insurance

330 (9.4)

Hemoglobin, g/dl

13.2 (11.8, 14.4)

Medicare

2,038 (58.3)

Medicaid

317 (9.1)

High school
Some college

BUN, mg/dl
Sodium, mmol

Highest level of education
Less than high school

Serum creatinine, mg/dl

425 (12.2)
1,187 (34.0)
1,094 (31.3)

<30
30–45

4–yr college

440 (12.6)

45–60

348 (10.0)

>60

<$25,000

Missing
1,076 (30.8)

139 (137, 141)

eGFR, ml/min/m2

Graduate or other professional degree
Total household income

1.1 (0.9, 1.4)
20.0 (16.0, 28.0)

122 (3.5)
304 (8.7)
491 (14.1)
1,200 (34.3)
1,377 (39.4)

Medication on enrollment

$25,000–$49,999

685 (19.6)

ACE inhibitor/ARB

2,102 (60.2)

$50,000–$74,999

417 (11.9)

Beta-blocker

2,894 (82.8)

$75,000–$99,999

212 (6.1)

MRA

$100,000–$149,999

184 (5.3)

ARNI

$150,000 or more

95 (2.7)

Employee status

Loop diuretic agent

1,161 (33.2)
451 (12.9)
2,139 (61.2)

Hydralazine

193 (5.5)

496 (14.2)

Digoxin

475 (13.6)

Part–time

252 (7.2)

Ivabradine

Disability for medical reasons

877 (25.1)

Inotrope

Full-time

Not employed for other reasons

1,869 (53.5)

Medical history
COPD

Number of medications

42 (1.2)
14 (0.4)
3.0 (2.0, 4.0)

Site characteristics
1,054 (30.2)

Physician specialty

CKD

693 (19.8)

Family practice

219 (6.3)

Depression

874 (25.0)

Internal medicine

266 (7.6)

Diabetes mellitus
Tobacco use/smoking

1,426 (40.8)
689 (19.7)

Atrial ﬁbrillation

1,258 (36.0)

Coronary artery disease

2,177 (62.3)

Hyperlipidemia

2,643 (75.6)

Hypertension

2,872 (82.2)

VT/VF

661 (18.9)

CRT therapy

234 (6.7)

NYHA functional classiﬁcation
I

344 (9.8)

II

1,914 (54.8)

III

1,004 (28.7)

IV
Unknown

HF specialist

718 (20.5)

Other cardiologist

2,086 (59.7)

Number of HF patients managed annually

1,200 (480, 3,000)

Values are median (Q1, Q3) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
ARNI ¼ angiotensin-receptor neprilysin inhibitor; BMI ¼ body mass index; BUN ¼
blood urea nitrogen; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive
pulmonary disease; CRT ¼ cardiac resynchronization therapy; eGFR ¼ estimated
glomerular ﬁltration rate; HbA1c ¼ Hemoglobin A1c; HF ¼ heart failure; LVEF ¼
left ventricular ejection fraction; MRA ¼ mineralocorticoid antagonist; VT/VF ¼
ventricular tachycardia/ventricular ﬁbrillation.

87 (2.5)

better health status (fewer symptoms, less social

145 (4.1)

or physical limitations, and better quality of life).

Continued in the next column

KCCQ-12 is a valid, reliable, and sensitive 12-item HF-

A 5-point change in KCCQ-os is considered a clinically
meaningful difference in scores from both patients’

speciﬁc patient-reported outcome form that quan-

and providers’ perspectives (7,8). For descriptive

tiﬁes patients’ HF symptoms, physical and social

purposes, the KCCQ-os was divided (9) into poor

limitations, and quality of life (4,6). KCCQ-12 domains

health status (score: <25), fair health status (score: 25

can be summarized as an overall summary score that

to 49), good health status (score: 50 to 74), and

ranges from 0 to 100, where higher scores reﬂect

excellent health status (score: 75 to 100). SES was
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F I G U R E 1 Patient Exclusion Flowsheet

T A B L E 2 Distribution of KCCQ-os Score by Patient Subgroup

(N ¼ 3,494)

Age, yrs

3,552 Patients Enrolled
and Data Abstracted
34 Patients Ineligible

<40

61.2  26.1 62.5 (40.1, 85.9)

40–64

61.9  25.0 63.9 (43.8, 83.3)

65–80

66.5  22.6 68.8 (50.0, 84.9)

>80

63.4  23.7 64.6 (44.8, 83.9)

Sex

3,518 Patients
• 14 Patients with Unavailable
KCCQ-os Data
• 10 Patients with Unavailable
Demographic Data

Male

65.9  23.7 68.8 (47.9, 85.4)

Female

60.3  23.8 61.5 (43.8, 80.2)

Race
White

64.9  23.4 67.7 (47.9, 84.4)

Black

60.5  25.2 61.2 (41.7, 82.3)

Hispanic

59.1  21.0 58.3 (43.8, 75.0)

Insurance status

3,494 Patients in
Study Cohort Analysis

Managed care

68.2  24.1

71.9 (51.6, 88.5)

Private insurance

70.2  22.1

73.4 (55.7, 88.5)

Medicare

63.7  23.3 65.1 (46.4, 82.3)

Medicaid

56.1  24.6 54.2 (38.5, 76.6)

Highest level of education

characterized as total annual household income and
assessed by asking patients to use ordinal categories
of annual household income ranging from <$25,000
to >$150,000 per year.
STATISTICAL ANALYSIS. Distribution of continuous

KCCQ-os scores was described by mean  SD, median,

Less than high school

58.3  23.2 57.3 (41.7, 76.6)

High school

62.5  24.0 64.6 (44.8, 81.8)

Some college

65.3  24.2 67.7 (46.9, 85.9)

4-yr college

67.8  22.9

Graduate or other professional
degree

69.8  22.2 75.0 (53.4, 87.5)

71.1 (51.3, 87.5)

Total household income
<$25,000

57.1  23.2 56.3 (40.6, 75.0)

and 25th and 75th percentiles according to patient

$25,000–$49,999

63.1  24.2 66.1 (44.3, 83.3)

characteristics that included sex, race/ethnicity, and

$50,000–$74,999

68.8  22.6 71.9 (53.1, 87.5)

SES. We then used hierarchical linear regression

$75,000–$99,999

69.9  22.6 75.0 (56.3, 87.5)

models, with site as a random effect to account for

$100,000–$149,999

73.5  20.9 77.1 (58.9, 92.2)

clustering within sites, to identify patient character-

$150,00 or More

74.6  21.0 83.3 (62.5, 89.6)

istics associated with patients’ health status. Our ﬁrst

Employment status

model incorporated patient sociodemographic and

74.6  21.9 80.2 (62.5, 91.7)

Working full-time
Working part-time

70.7  22.6

77.1 (57.3, 88.5)

clinical characteristics (model 1) with subsequent

Disability for medical reasons

52.9  23.7

52.1 (34.9, 70.8)

adjustment for medical therapies (model 2) present

Not employed for other reasons

65.9  22.6 68.8 (49.0, 84.4)

on enrollment. Backward selection was performed to
obtain the ﬁnal models. Full models included all
variables shown in Table 1, except for laboratory re-

Values are mean  SD and median (Q1, Q3).
KCCQ-os ¼ Kansas City Cardiomyopathy Questionnaire-overall summary score.

sults. Age, sex, and race/ethnicity were permanently
retained in the model. The maximum p value for

most

covariates to be retained in the model was set at 0.05.

imputed as “no.” All estimates were reported using

The relationship between mean KCCQ-os score and

95% conﬁdence intervals (CIs) and an a ¼ 0.05 was

continuous variables are reported in units of 1 SD,

common

value.

Missing

procedures

were

used to determine statistical signiﬁcance. All analyses

except for age, which was reported per 10 year in-

were performed using SAS software version 9.4 (SAS

tervals. We tested the nonlinearity by using restricted

Institute, Cary, North Carolina). Analyses were per-

cubic splines. There was no evidence of nonlinearity

formed independently by Duke Clinical Research

except for age, and therefore we used a linear spline

Institute, and the lead author takes responsibility for

with a knot of 70 for age.

guiding data analysis and interpretation of the results.

Rates of missing data for patient-level variables,
overall, were small (<8%), except for household in-

RESULTS

come, which was not reported by w24% of patients.
Missing values for continuous variables were imputed

A total of 3,552 patients were enrolled in the CHAMP-

using the sex/age/KCCQ group-speciﬁc median for

HF registry before March 6, 2017. Of that sample, our

patient-level covariates. For categorical variables,

ﬁnal analytic cohort consisted of 3,494 patients

missing medical history variables were imputed to the

across 140 sites after excluding patients with missing
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KCCQ-os data (n ¼ 14), demographic data (n ¼ 10), and
those ineligible according to the study protocol
(n ¼ 34) (Figure 1). There was a broad range of patient-

T A B L E 3 Model 2: Unadjusted and Adjusted Association Between Patient Characteristics

and Medications at Enrollment with KCCQ-os (N ¼ 3,494)
Unadjusted Effect
(95% CI)

reported KCCQ-os scores, encompassing poor (n ¼
228), fair (n ¼ 785), good (n ¼ 1,101), and excellent

#70 yrs

PATIENT CHARACTERISTICS AND HEALTH STATUS

$70 yrs

cohort are described in Tables 1 and 2, with information
on medication prescription by sex, race/ethnicity,
and SES provided in Online Tables 3a to 3d and New
York Heart Association (NYHA) functional classiﬁca-

p Value

Adjusted Effect
(95% CI)

p Value

Age, 10-yr increments

(n ¼ 1,380) health status.
ACROSS SUBGROUPS. Characteristics of the analytic

469
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1.2 (0.5 to 1.8)

<0.001

0.2 (1.7 to 1.3)

1.6 (0.6 to 2.6)

0.002

0.765

5.5 (7.5 to 3.4)

<0.001

4.8 (6.5 to 3.1)

<0.001

2.2 (3.8 to 0.6)

0.007

Black

4.5 (6.7 to 2.2)

<0.001

0.4 (2.5 to 1.8)

0.736

Other

0.1 (2.8 to 3.1)

0.930

3.1 (0.3 to 5.9)

0.031

3.4 (6.1 to 0.6)

0.016

4.0 (6.6 to 1.3)

0.003

3.3 (4.0 to 2.5)

<0.001

2.5 (3.3 to 1.8)

<0.001

Female (ref: male)
Race/ethnicity (ref: white)

Hispanic (ref: nonHispanic)

tion by sex, in Online Table 3e. Of the total sample, the

BMI to per 7.2 U

median age was 68.0 (interquartile range [IQR]: 59.0 to

Total household income
(ref: <$25,000)

75.0) years, with more men than women (70.8% vs.

$25,000–$49,999

4.8 (2.6 to 7.1)

<0.001

0.7 (1.4 to 2.8)

0.505

29.2%) and white (74.9%) than black (16.4%) or His-

$50,000–$74,999

10.1 (7.5 to 12.7)

<0.001

3.2 (0.7 to 5.7)

0.013

panic (16.9%) patients. The total annual household

$75,000–$99,999

10.8 (7.4 to 14.2)

<0.001

3.8 (0.6 to 7.0)

0.019

income was <$25,000 in 30.8% of participants,

$100,000–$149,999

14.2 (10.6 to 17.8)

<0.001

4.7 (1.3 to 8.1)

0.007

whereas 2.7% reported incomes >$150,000. A signiﬁ-

$150,000 or more

cant proportion had concomitant diagnoses of atrial
ﬁbrillation, coronary artery disease, chronic obstruc-

Prefer not to answer

Working part-time

Finally, median documented LVEF was 30% (IQR: 23%,

Disability for medical
reasons

ulation, 87.6% of the cohort had no or only one hos-

Not employed for other
reasons

pitalization within 12 months of enrollment in the

COPD

registry.

Chronic kidney disease

In regard to HF-related quality of life, the mean
KCCQ-os score was 64.2  23.9 in the overall sample.
Participants with good to excellent health status were
more often older ($65), male, and white. Online

<0.001
0.267

1.8 (3.3 to 0.2)

0.029

2.8 (6.1 to 0.6)

0.107

1.3 (4.5 to 1.9)

0.417

Depression

20.4 (22.8 to 17.9) <0.001 14.3 (16.8 to 11.8) <0.001
7.4 (9.6 to 5.2)

<0.001

10.4 (12.1 to 8.7)

<0.001

6.2 (7.7 to 4.6)

6.4 (8.3 to 4.4)

<0.001

2.6 (4.4 to 0.8)

0.005

10.5 (12.3 to 8.7)

<0.001

7.3 (9.0 to 5.7)

<0.001

0.015

2.0 (3.5 to 0.5)

0.011

0.267

1.8 (3.3 to 0.2)

0.029

Prior HF hospitalization in
past year (ref: 0)
5.2 (7.1 to 3.4)

Pulse, per 12.5 beats/min

<0.001

2.8 (4.5 to 1.2)

0.001

13.2 (15.6 to 10.7) <0.001

6.6 (8.9 to 4.3)

<0.001

4.0 (4.8 to 3.2)

<0.001

2.4 (3.1 to 1.7)

<0.001

<0.001

1.1 (0.4 to 1.9)

DIFFERENCES IN HEALTH STATUS BY SEX, RACE/

LVEF, per 8%

2.2 (1.5 to 3.0)

ETHNICITY, AND SES STATUS. Signiﬁcant differences

ARNI

1.2 (1.3 to 3.6)

ACEi/ARB

3.6 (2.0 to 5.2)

variability was modestly attenuated after adjusting

<0.001

2.0 (3.6 to 0.4)

1

(4.8 points; 95% CI: 6.5 to 3.1; p < 0.001). This

5.0 (7.4 to 2.5)

0.9 (2.6 to 0.7)

$2

model, women had worse KCCQ-os scores than men

<0.001

Atrial ﬁbrillation

subgroup characteristics by ranges of KCCQ-os scores.

adjusted and adjusted analyses. In the unadjusted

0.045

Coronary artery disease

Table S1 provides a detailed overview of patient

in KCCQ-os scores by sex were observed in both un-

4.7 (0.1 to 9.2)

Employment status
(ref: working full-time)

tive lung disease, diabetes mellitus, and hypertension.
35%). Supporting the stability of this outpatient pop-

15.3 (10.4 to 20.1)
0.9 (2.6 to 0.7)

0.3474
<0.001

0.003

3.9 (1.5 to 6.4)

0.002

3.6 (2.0 to 5.3)

<0.001

8.2 (9.8 to 6.6)

<0.001

Ivabradine

10.2 (17.2 to 3.2)

0.004

6.9 (13.2 to 0.6)

0.033

Inotrope

25.8 (37.9 to 13.6) <0.001 17.0 (27.9 to 6.1)

0.002

Loop diuretic agent

4.4 (6.0 to 2.9)

Abbreviations as in Table 1.

for other patient-level characteristics in model 1
(2.2 points; 95% CI: 3.7 to 0.6; p ¼ 0.007) (Online
Table S2), and remained statistically signiﬁcant even

insigniﬁcant after adjusting for medical therapies

after adjusting for HF medications (2.2 points; 95%

(0.4 points; 95% CI: 2.5 to 1.8; p ¼ 0.736) (Table 3).

CI: 3.8 to 0.6; p ¼ 0.007) (Table 3). Differences by

For

race/ethnicity were observed in unadjusted analyses,

remained after adjusting only for patient character-

with blacks (4.5 points; 95% CI: 6.7 to 2.2;

istics in model 1 (3.4 points; 95% CI: 6.0 to 0.8;

p < 0.001) and Hispanics (3.4 points; 95% CI: 6.1

p ¼ 0.011) (Online Table S2) and then medications

Hispanics,

clinically

signiﬁcant

differences

to 0.6; p ¼ 0.016) having worse health status scores

(4.0 points; 95% CI: 6.6 to 1.3; p ¼ 0.003) (Table 3)

than those of whites. For blacks, this difference was

in model 2.

fully explained after the addition of other patient

Finally, large differences by household income

characteristics to model 1 (0.7 points; 95% CI: 2.9

were observed between the highest- and lowest-paid

to 1.4; p ¼ 0.52) (Online Table 2) and remained

groups across unadjusted and adjusted analyses.

<0.001
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F I G U R E 2 Unadjusted and Adjusted Mean KCCQ-os Score Disparities by Sex, Race/Ethnicity, and Socioeconomic Status

P-Value

P-Value

Female

-4.8 (-6.5, -3.1) <0.001

Black Race

-4.5 (-6.7, -2.2) <0.001

-2.2 (-3.8, -0.6) 0.007
-0.4 (-2.5, 1.8)

Hispanic

-3.4 (-6.1, -0.6) 0.016

-4.0 (-6.6, -1.3) 0.003

0.736

Total Household Income
<0.001

0.7 (-1.4, 2.8)

0.505

10.1 (7.5, 12.7) <0.001

4.8 (2.6, 7.1)

3.2 (0.7, 5.7)

0.013

$75,000-$99,999

10.8 (7.4, 14.2) <0.001

3.8 (0.6, 7.0)

0.019

$100,000-$149,999

14.2 (10.6, 17.8) <0.001

4.7 (1.3, 8.1)

0.007

$150,000 or more

15.3 (10.4, 20.1) <0.001

4.7 (0.1, 9.2)

0.045

$25,000-$49,999
$50,000-$74,999

-10

-5

0

5

10

15

20

-6

-4

-2

0

2

4

6

8

10

Candidate variables considered for multivariate analyses were age, sex, race, BMI, insurance status, highest level of education, house income, employment status,
diabetes mellitus, CKD, COPD, depression, tobacco use/smoking, atrial ﬁbrillation, CAD, hypertension, hyperlipidemia, ventricular tachycardia/ﬁbrillation, CRT, number
of prior HF hospitalizations, systolic blood pressure, heart rate, LVEF, ACEi/ARB, beta-blocker, MRA, ARNI, loop diuretic agent, hydralazine, digoxin, ivabradine, inotrope, and number of HF medications. Variables included in multivariate analysis after backward selection were age, sex, race, BMI, house income, employment status,
CKD, COPD, depression, atrial ﬁbrillation, number of prior HF hospitalizations, systolic blood pressure, heart rate, LVEF, ARNI, loop diuretic therapy, ivabradine, and
inotrope. Reference category for sex was male. Reference category for race/ethnicity was white. Reference category for total household income was <$25,000
(annually). ACEi/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ARNI ¼ angiotensin-receptor neprilysin inhibitor; BMI ¼ body mass
index; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; HF ¼
heart failure; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid antagonist; other abbreviations as in Tables 1 and 2.

In the unadjusted model, patients with the highest

HFrEF in outpatient clinical practice, women, blacks

level had a mean KCCQ-os score that was 15.3

and Hispanics, and lower-income patients had statis-

points higher than those with the lowest income

tically signiﬁcantly worse HF-speciﬁc health status in

(95% CI: 10.4 to 20.1; p < 0.001). This variability was

unadjusted analyses. Moreover, even after adjust-

attenuated but still signiﬁcantly different after

ment for numerous patient and treatment factors, a

adjustment for other patient characteristics in model

small but statistically signiﬁcant worse KCCQ-os score

1 (5.6 points; 95% CI: 1.0 to 10.2; p ¼ 0.02) (Online

remained in women, Hispanics, and poorer patients.

Table 2) and persisted after adjusting for medical

CHAMP-HF is a contemporary registry that, for the

therapies in model 2 (4.7 points; 95% CI: 0.1 to 9.2;

ﬁrst time, captures the care and outcomes of patients

p ¼ 0.045) (Table 3). A test for trend across all

with HFrEF. Our ﬁndings describe signiﬁcant dispar-

income levels was signiﬁcant for both unadjusted

ities in the control of HF symptoms and optimization

(p < 0.0001) and adjusted (p ¼ 0.003) models.

of function and quality of life between women and

Both unadjusted and fully adjusted models for sex,

men, whites and Hispanics, and those with lower and

race/ethnicity, and SES are shown in Figure 2.

higher SES that warrant further efforts to achieve the
goals of equity in health care.

DISCUSSION

Our ﬁndings extend previous efforts to describe
disparities in the care of patients with HF by doc-

A primary goal for treating patients with HFrEF is to

umenting differences in patients’ health status across

minimize their symptoms and optimize their function

different sociodemographic groups. Thus, although

and quality of life (10). To accomplish this goal, cli-

prior efforts have described sociodemographic dis-

nicians have a range of established and emerging

parities in relation to cardiovascular mortality and

medical and device therapies (11–13), but whether

routine implementation of guideline-directed HFrEF

these are applied with similar success to optimize the

therapies, insights into health status disparities are

health status of patients with different sex, race/

limited (14–16). For example, in regard to sex, our

ethnicity, and SES is unknown. In the present study,

results substantially extend several prior, smaller

we used data from CHAMP-HF to explore disparities

studies suggesting better (17,18), worse (19–26), or

in health status by sex, race/ethnicity, and SES. We

comparable (27) quality of life in women. Our analysis

found that, among a large population of patients with

describes

health

status

in

a

larger,

more
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contemporary stable HFrEF population. When inter-

be overcome with more aggressive therapy, an

preting our ﬁndings, we believe it is important to

important future research priority.

focus upon the unadjusted, as opposed to only

Our results concerning Hispanics are novel in that

adjusted, effect sizes. Although adjusting for con-

they contradict earlier reports that Latin Americans

founders is very important in observational research

experienced comparable health status, on initial

seeking to associate patient characteristics with out-

evaluation, compared to other ethnic and racial groups

comes, in this case, we do not believe that there is a

(33,36). As our study is descriptive (and the ﬁrst to

biologically plausible reason why clinicians should be

report differences in the health status of Hispanics), we

less capable of controlling the symptoms and opti-

cannot provide causal insights into these observations.

mizing the quality of life of women than that of men.

Finally, our ﬁndings are most indicative of sizeable

Finding a clinically important difference in KCCQ-os

variability in HF-speciﬁc health status based on

scores in women from this large multicenter registry

ﬁnancial income, with similar patterns having been

suggests that we are not being as effective in opti-

previously described (19,37–39). In our study, we

mizing the health status of women with HFrEF

leveraged annual household income as a proxy for

and that more research is needed to better under-

SES, which coincides with deﬁnitions used previously

stand how to overcome these apparent sex-level

in published reports (18). Overall, our results can be

disparities. For example, prior studies associating

understood in the context of routine HF management,

female sex with lower adherence to guideline-

where chronic illness is predictably disabling and

directed HFrEF therapies may be one possible mech-

thereby forces patients to make signiﬁcant lifestyle

anism of health status inequality, although we did

changes that have an impact on overall quality of life.

account for differences in treatment in our analyses

By extension, an adequate ﬁnancial income provides

(17). Whether, as others have suggested, these

an uninterrupted layer of insulation against barriers to

differences are due to HF management knowledge,

self-care created by inadequate resources (37).

perceived

control,

self-care

conﬁdence

(28),

or

One strategy that may help address these observed

competing demands between family responsibilities,

disparities would be to routinely capture and report

sex roles, and self-care (29–31) is unknown and

patient-reported health status in clinical care, a

further studies are needed to identify how to deliver

means of transparently and reproducibly document-

care that is more equitable between men and women

ing the symptoms, function, and quality of life of

with HFrEF (32).

patients with HF at each and every clinic visit. By

Health disparities between whites and nonwhites

consistently capturing and reporting patients’ health

are well known, but racial variability in HF-speciﬁc

status, clinicians could readily identify those for

health status remains understudied (20,33,34). Our

whom additional therapeutic strategies may be

ﬁndings parallel prior research that has shown poorer

needed to improve their management. Toward that

perceived HF-related health (18) and steeper func-

end, a new Medicare framework (40,41) has been

tional decline (34) in blacks, although other studies

designed to reward providers for collecting patient-

have failed to observe any racially driven associations

reported

with health status during outpatient follow-up (35).

Centers for Medicare and Medicaid Services Merit-

Although results of our fully adjusted model showed

Based Payment System. However, although the

no signiﬁcant differences in health status between

Centers for Medicare and Medicaid Services has

whites and blacks, it remains noteworthy that unad-

created a mechanism to encourage the collection of

justed health status differences between those groups

patient-reported outcomes measurements, the means

were statistically and clinically signiﬁcant (w5 points

of feasibly collecting, scoring, and reporting these

lower in blacks). This highlights an important reality

data at the time of a clinical visit will require further

in the management of the HFrEF population, in that

work. Although it is possible that the routine collec-

African Americans have worse health status, whether

tion of patients’ health status can reduce these health

mediated by an underlying biological mechanism or

status disparities, this will require further investiga-

other sociodemographic patient characteristics, and

tion after the implementation of patient-reported

outcomes

measurements

through

the

this should not be overlooked as part of routine

outcome-based performance measures.

outpatient care. Multiple reasons for this variability

STUDY LIMITATIONS. Our ﬁndings must be inter-

in health status have been postulated, including cul-

preted in context of the following limitations. First,

tural differences in what constitutes health and fac-

although the CHAMP-HF registry is among the largest

tors considered during self-evaluation of health

cross-sectional assessments of the health status of

status (18), although there have been no reports

patients in routine clinical care, it was conducted in

suggesting that these observed differences might not

voluntary participating sites committed to clinical
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research. Whether these ﬁndings are generalizable

hospitalization rates extend to patients’ health status

throughout the United States is unknown, and our

and underscore the need for novel strategies to

estimates of health status disparities may not accu-

reduce health status disparities as well as future work

rately reﬂect the entire country. Second, our analysis

to better understand their complexity.

assessed health status at a single point in time
(enrollment), and further work will be needed to

ADDRESS FOR CORRESPONDENCE:

describe the trajectories of patients’ health status

Spertus, Saint Luke’s Mid America Heart Institute,

over time. Third, one-fourth of patients did not report

4401 Wornall Road, Kansas City, Missouri 64111.

annual household income, and this was treated as a

E-mail: spertusj@umkc.edu.

Dr. John A.

separate category. Fourth, residual measured or unmeasured confounding might have inﬂuenced the

PERSPECTIVES

associations observed. Fifth, the use of multiple
comparisons might have inﬂuenced the statistical
signiﬁcance and interpretation of ﬁnal p values. Sixth
and ﬁnally, this initial, descriptive report was not
able to formally test mediators of observed difference
in health status across vulnerable groups nor deﬁne
practice patterns that might support intervention to
reduce these disparities.

HFrEF, we found that women, blacks, and Hispanics
and patients with lower income signify unique populations that may beneﬁt from more aggressive HF
follow-up and treatment in the outpatient setting.

describes the association between HFrEF patients’

In analyzing a unique, prospective observational
registry of patients with chronic HFrEF, we found
that women, blacks, and Hispanics and patients with
lower socioeconomic status had worse symptoms,
function, and health-related quality of life. After
multivariate adjustment, clinically signiﬁcant disparities remained across sex, race/ethnicity, and
socioeconomic groups. Our ﬁndings indicate that
reported

ﬁrst large assessment of health status in patients with

TRANSLATIONAL OUTLOOK: This analysis

CONCLUSIONS

previously

COMPETENCY IN MEDICAL KNOWLEDGE: In the

disparities

in

survival

health status and medical and sociodemographic
characteristics at enrollment in an observational
registry in a contemporary clinical setting. Future studies
will be needed to identify health status trajectories
over time as well as detect practice patterns that
might reduce health status disparities by sex, race/
ethnicity, and socioeconomic status in this high-risk
population.

and
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